Abstract
Background
The liver manifestations of Alagille syndrome (ALGS) are highly variable, and factors affecting its prognosis are poorly understood. We asked whether the composition of bile acids in ALGS patients with good clinical outcomes differs from that in patients with poor outcomes and whether bile acids could be used as prognostic biomarkers.
Methods
Blood for bile acid profiling was collected from genetically confirmed JAG1-associated ALGS patients before one year of age. A good prognosis was defined as survival with native liver and total bilirubin (TB) < 85.5 μmol/L, while a poor prognosis was defined as either liver transplantation, death from liver failure, or TB ≥ 85.5 μmol/L at the last follow-up.
Results
We found that the concentrations of two poly-hydroxylated bile acids, tauro‐2β,3α,7α,12α-tetrahydroxylated bile acid (THBA) and glyco-hyocholic acid (GHCA), were significantly increased in patients with good prognosis compared to those with poor prognosis [area under curve (AUC) = 0.836 and 0.782, respectively] in the discovery cohort. The same trend was also observed in the molar ratios of GHCA to glyco- chenodeoxycholic acid (GCDCA) and tetrahydroxylated bile acid (THCA) to tauro-chenodeoxycholic acid (TCDCA) (both AUC = 0.836). A validation cohort confirmed these findings. Notably, tauro‐2β,3α,7α,12α-THBA achieved the highest prediction accuracy of 88.00% (92.31% sensitivity and 83.33% specificity); GHCA at > 607.69 nmol/L was associated with native liver survival [hazard ratio: 13.03, 95% confidence interval (CI): (2.662–63.753), P = 0.002].
Conclusions
We identified two poly-hydroxylated bile acids as liver prognostic biomarkers of ALGS patients. Enhanced hydroxylation of bile acids may result in better clinical outcomes.
Similar content being viewed by others
Data availability statement
All data generated or analyzed during this study are included in this published article and its supplementary information files. And the primary data would be available on request from the authors.
References
Kamath BM, Ye W, Goodrich NP, Loomes KM, Romero R, Heubi JE, et al. Outcomes of childhood cholestasis in alagille syndrome: results of a multicenter observational study. Hepatol Commun. 2020;4:387–98.
Gilbert MA, Bauer RC, Rajagopalan R, Grochowski CM, Chao G, McEldrew D, et al. Alagille syndrome mutation update: comprehensive overview of JAG1 and NOTCH2 mutation frequencies and insight into missense variant classification. Hum Mutat. 2019;40:2197–220.
Kamath BM, Piccoli DA. Liver disease in children. 3rd ed. New York: Cambridge University Press; 2007.
Kamath BM, Bason L, Piccoli DA, Krantz ID, Spinner NB. Consequences of JAG1 mutations. J Med Genet. 2003;40:891–5.
Spinner NB, Colliton RP, Crosnier C, Krantz ID, Hadchouel M, Meunier-Rotival M. Jagged1 mutations in alagille syndrome. Hum Mutat. 2001;17:18–33.
Kamath BM, Baker A, Houwen R, Todorova L, Kerkar N. Systematic review: the epidemiology, natural history, and burden of Alagille syndrome. J Pediatr Gastroenterol Nutr. 2018;67:148–56.
Emerick KM, Rand EB, Goldmuntz E, Krantz ID, Spinner NB, Piccoli DA. Features of Alagille syndrome in 92 patients: frequency and relation to prognosis. Hepatology. 1999;29:822–910.
Mouzaki M, Bass LM, Sokol RJ, Piccoli DA, Quammie C, Loomes KM, et al. Early life predictive markers of liver disease outcome in an international, multicentre cohort of children with Alagille syndrome. Liver Int. 2016;36:755–60.
Chiang JYL. Bile acid metabolism and signaling in liver disease and therapy. Liver Res. 2017;1:3–9.
Monte MJ, Marin JJ, Antelo A, Vazquez-Tato J. Bile acids: chemistry, physiology, and pathophysiology. World J Gastroenterol. 2009;15:804–16.
Hofmann AF, Hagey LR. Key discoveries in bile acid chemistry and biology and their clinical applications: history of the last eight decades. J Lipid Res. 2014;55:1553–95.
Wang R, Sheps JA, Ling V. ABC transporters, bile acids, and inflammatory stress in liver cancer. Curr Pharm Biotechnol. 2011;12:636–46.
Fickert P, Wagner M. Biliary bile acids in hepatobiliary injury - what is the link? J Hepatol. 2017;67:619–31.
Alnouti Y. Bile acid sulfation: a pathway of bile acid elimination and detoxification. Toxicol Sci. 2009;108:225–46.
Morita SY, Ikeda Y, Tsuji T, Terada T. Molecular mechanisms for protection of hepatocytes against bile salt cytotoxicity. Chem Pharm Bull (Tokyo). 2019;67:333–40.
Han J, Liu Y, Wang R, Yang J, Ling V, Borchers CH. Metabolic profiling of bile acids in human and mouse blood by LC-MS/MS in combination with phospholipid-depletion solid-phase extraction. Anal Chem. 2015;87:1127–36.
Caussy C, Hsu C, Singh S, Bassirian S, Kolar J, Faulkner C, et al. Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD. Aliment Pharmacol Ther. 2019;49:183–93.
Rejchrt S, Hroch M, Repak R, Fejfar T, Douda T, Kohoutova D, et al. Investigation of 23 bile acids in liver bile in benign and malignant biliary stenosis: a pilot study. Gastroenterol Res Pract. 2019;2019:5371381.
Sheps JA, Wang R, Wang J, Ling V. The protective role of hydrophilic tetrahydroxylated bile acids (THBA). Biochim Biophys Acta Mol Cell Biol Lipids. 2021;1866:158925.
Liu T, Wang RX, Han J, Hao CZ, Qiu YL, Yan YY, et al. Comprehensive bile acid profiling in hereditary intrahepatic cholestasis: genetic and clinical correlations. Liver Int. 2018;38:1676–85.
Lee CS, Kimura A, Wu JF, Ni YH, Hsu HY, Chang MH, et al. Prognostic roles of tetrahydroxy bile acids in infantile intrahepatic cholestasis. J Lipid Res. 2017;58:607–14.
Fuchs CD, Paumgartner G, Wahlstrom A, Schwabl P, Reiberger T, Leditznig N, et al. Metabolic preconditioning protects BSEP/ABCB11(-/-) mice against cholestatic liver injury. J Hepatol. 2017;66:95–101.
Megaraj V, Iida T, Jungsuwadee P, Hofmann AF, Vore M. Hepatobiliary disposition of 3alpha,6alpha,7alpha,12alpha-tetrahydroxy-cholanoyl taurine: a substrate for multiple canalicular transporters. Drug Metab Dispos. 2010;38:1723–30.
Wang R, Salem M, Yousef IM, Tuchweber B, Lam P, Childs SJ, et al. Targeted inactivation of sister of P-glycoprotein gene (spgp) in mice results in nonprogressive but persistent intrahepatic cholestasis. Proc Natl Acad Sci U S A. 2001;98:2011–6.
Wang R, Sheps JA, Liu L, Han J, Chen PSK, Lamontagne J, et al. Hydrophilic bile acids prevent liver damage caused by lack of biliary phospholipid in Mdr2(-/-) mice. J Lipid Res. 2019;60:85–97.
Liu T, Wang RX, Han J, Qiu YL, Borchers CH, Ling V, et al. Changes in plasma bile acid profiles after partial internal biliary diversion in PFIC2 patients. Ann Transl Med. 2020;8:185.
Warner S, Kelly DA. Liver failure in pediatric gastrointestinal and liver disease (sixth edition). Amsterdam: Elsevier; 2021.
Zheng J, Ye C, Hu B, Yang H, Yao Q, Ma J, et al. Bile acid profiles in bile and feces of obese mice by a high-performance liquid chromatography-tandem mass spectrometry. Biotechnol Appl Biochem. 2021;68:1332–41.
Mao F, Liu T, Hou X, Zhao H, He W, Li C, et al. Increased sulfation of bile acids in mice and human subjects with sodium taurocholate cotransporting polypeptide deficiency. J Biol Chem. 2019;294:11853–62.
Bathena SP, Mukherjee S, Olivera M, Alnouti Y. The profile of bile acids and their sulfate metabolites in human urine and serum. J Chromatogr B Analyt Technol Biomed Life Sci. 2013;942–3:53–62.
Acknowledgements
The authors are grateful for the support of the families we have studied, and would also like to thank the referring physicians, nurses, and technical staff. We thank Prof. Ying-Jie Zheng (yjzheng@fudan.edu.cn) as an independent statistician for his statistical guidance. This research was supported by the National Key Research and Development Program of China (Grant No. 2021YFC 2700800), the National Natural Science Foundation of China (81741056, 81873543), and the Natural Science Foundation of Shanghai (20YF1402900).
Funding
National Key Research and Development Program of China (No. 2021YFC 2,700,800 to J-S W. National Natural Science Foundation of China (No. 81741056 to WJS). National Natural Science Foundation of China (No. 81873543 to WJS). Natural Science Foundation of Shanghai (20YF1402900 to T L).
Author information
Authors and Affiliations
Contributions
WMX, HJ, and LT contributed equally to this paper. WMX: data curation, formal analysis, investigation, project administration, software, validation, visualization, writing–original draft. HJ: formal analysis, methodology, software, writing–review and editing. LT: conceptualization, funding acquisition, project administration. WRX: writing–review and editing. LLT: data curation. LZD: data curation. YJC: formal analysis, methodology. LLL: data curation. LY: data curation. XXB: data curation. GJY: data curation. LSY: data curation. ZL: formal analysis, methodology, software. LV: writing–review and editing. WJS: conceptualization, funding acquisition, project administration, supervision, writing–original draft, writing–review and editing.
Corresponding author
Ethics declarations
Conflict of interest
No financial or non-financial benefits have been received or will be received from any party related directly or indirectly to the subject of this article.
Ethical approval
The study was approved by the Ethics Committee of Children’s Hospital of Fudan University (Shanghai, China) (No. 2017-99) following the ethical standards of the institutional committee on human experimentation and with the Helsinki Declaration of 1964, as revised in 2000. Informed consent to participate in the study has been obtained from participants or their parent or legal guardian in the case of children under 16.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Wang, MX., Han, J., Liu, T. et al. Poly-hydroxylated bile acids and their prognostic roles in Alagille syndrome. World J Pediatr 19, 652–662 (2023). https://doi.org/10.1007/s12519-022-00676-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12519-022-00676-5